Despite posting overall sound numbers for the three-month period, the drugmaker's stock still dropped by 2. Investors were apparently displeased with the quarterly sales figures for the plaque psoriasis medication Taltz, the diabetes drug Trulicity, and the migraine medicine Emgality.

Lilly, after all, is still navigating its way through a maze of patent expires for top-selling medicines such as Cialis, the overhang from the spinoff of its animal health unit Elancoand the raging controversy over insulin prices in the U. Let's check out how Lilly's stock compares to its biopharma peer group on several key factors. From a surface level, Lilly comes across as a worthwhile buy.

Those are all favorable attributes for a big pharma stock. But the real test is how Lilly compares to the other Eli Lilly And Company Stock titans from a valuation, near-term sales growth, and forward annual dividend yield standpoint.

The table below reveals where Lilly stands in relation to its large-cap biopharmaceutical peers on these three key metrics. Bristol-Myers Squibb and Pfizer's projected sales were excluded from this comparison because of their ongoing business development plans. Data source: Yahoo! What this comparison shows is that Lilly sports a top-shelf valuation, Eli Lilly And Company Stock below-average dividend yield, and an only slightly above-average revenue growth outlook for Over the past five years, Lilly's stock generated the highest total returns on capital within its large-cap biopharma peer group when including dividends and assuming a dividend reinvestment planand it did so by a wide margin.

However, the drugmaker's shares have lagged behind its biopharma brethren in a big way this year -- specifically, Lilly's stock has lost investors over 5.

The core issue at play is that investors seem to have gotten 4040 Control Company bit too excited about Lilly's slate of new growth products. Starting this year, however, the harsh realities of the hypercompetitive biopharma space have started to become readily apparent, causing the drugmaker's shares to take a step backward. Unfortunately, Lilly's shares appear to have further to fall before they line up with the industry as a whole from Voylla Company valuation standpoint.

Oct 24, at AM. Author Bio George Budwell has been writing about healthcare and biotechnology companies at the Motley Eli Lilly And Company Stock since His primary interests are novel small molecule drugs, Eli Lilly And Company Stock generation vaccines, and cell therapies. Image Source: Getty Images. Stock Advisor Eli Lilly And Company Stock in February of Join Stock Advisor.

Related Articles. Is Eli Lilly Stock a Buy?

Eli Lilly and Company - Wikipedia

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries.Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Col. Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War. Lilly's notable achievements include being the first company to mass-produce the ...Headquarters: Indianapolis, Indiana, U.S.…